Terms: = Pancreatic cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4
377 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. Circular RNA circTATDN3 promotes the Warburg effect and proliferation in colorectal cancer.
Lin J; Zhong W; Lyu Z; Peng J; Rong Y; Zeng K; Lai J; Wu D; Wang J; Li Y; Zheng J; Zhang J; Pan Z
Cancer Lett; 2024 May; 589():216825. PubMed ID: 38548218
[TBL] [Abstract] [Full Text] [Related]
3. Impact of Histone Lysine Methyltransferase SUV4-20H2 on cancer Onset and Progression with Therapeutic Potential.
Papadaki S; Piperi C
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473745
[TBL] [Abstract] [Full Text] [Related]
4. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB8-C1 and NCC-GCTB9-C1.
Adachi Y; Noguchi R; Yoshimatsu Y; Sin Y; Osaki J; Ono T; Iwata S; Akiyama T; Tsuchiya R; Toda Y; Ishihara S; Ogura K; Kobayashi E; Kojima N; Yoshida A; Yokoo H; Kawai A; Kondo T
Hum Cell; 2024 May; 37(3):874-885. PubMed ID: 38466561
[TBL] [Abstract] [Full Text] [Related]
5. Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness.
Lin Q; Serratore A; Niu J; Shen S; Roy Chaudhuri T; Ma WW; Qu J; Kandel ES; Straubinger RM
Drug Resist Updat; 2024 Mar; 73():101064. PubMed ID: 38387284
[TBL] [Abstract] [Full Text] [Related]
6. Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma.
Cattaneo G; Ventin M; Arya S; Kontos F; Michelakos T; Sekigami Y; Cai L; Villani V; Sabbatino F; Chen F; Sadagopan A; Deshpande V; Moore PA; Ting DT; Bardeesy N; Wang X; Ferrone S; Ferrone CR
Cancer Lett; 2024 Apr; 587():216713. PubMed ID: 38364961
[TBL] [Abstract] [Full Text] [Related]
7. An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer.
Lutz MS; Wang K; Jung G; Salih HR; Hagelstein I
Front Immunol; 2024; 15():1343929. PubMed ID: 38322253
[TBL] [Abstract] [Full Text] [Related]
8. Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization.
Bauer N; Balourdas DI; Schneider JR; Zhang X; Berger LM; Berger BT; Schwalm MP; Klopp NA; Siveke JT; Knapp S; Joerger AC
ACS Chem Biol; 2024 Feb; 19(2):266-279. PubMed ID: 38291964
[TBL] [Abstract] [Full Text] [Related]
9. Dual-Hit Strategy for Therapeutic Targeting of pancreatic cancer in Patient-Derived Xenograft Tumors.
Roy Chaudhuri T; Lin Q; Stachowiak EK; Rosario SR; Spernyak JA; Ma WW; Stachowiak MK; Greene MK; Quinn GP; McDade SS; Clynes M; Scott CJ; Straubinger RM
Clin Cancer Res; 2024 Apr; 30(7):1367-1381. PubMed ID: 38270582
[TBL] [Abstract] [Full Text] [Related]
10. Altered histone acetylation patterns in pancreatic cancer cell lines induce subtype‑specific transcriptomic and phenotypical changes.
Zhou Q; Pichlmeier S; Denz AM; Schreiner N; Straub T; Benitz S; Wolff J; Fahr L; Del Socorro Escobar Lopez M; Kleeff J; Mayerle J; Mahajan UM; Regel I
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38240084
[TBL] [Abstract] [Full Text] [Related]
11. DAXX promotes centromeric stability independently of ATRX by preventing the accumulation of R-loop-induced DNA double-stranded breaks.
Pinto LM; Pailas A; Bondarchenko M; Sharma AB; Neumann K; Rizzo AJ; Jeanty C; Nicot N; Racca C; Graham MK; Naughton C; Liu Y; Chen CL; Meakin PJ; Gilbert N; Britton S; Meeker AK; Heaphy CM; Larminat F; Van Dyck E
Nucleic Acids Res; 2024 Feb; 52(3):1136-1155. PubMed ID: 38038252
[TBL] [Abstract] [Full Text] [Related]
12. EBF2 Links KMT2D-Mediated H3K4me1 to Suppress pancreatic cancer Progression via Upregulating KLLN.
Yao B; Xing M; Meng S; Li S; Zhou J; Zhang M; Yang C; Qu S; Jin Y; Yuan H; Zen K; Ma C
Adv Sci (Weinh); 2024 Jan; 11(2):e2302037. PubMed ID: 38015024
[TBL] [Abstract] [Full Text] [Related]
13. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors in pancreatic cancer.
Lin Q; Serratore A; Perri J; Roy Chaudhuri T; Qu J; Ma WW; Kandel ES; Straubinger RM
Br J Pharmacol; 2024 May; 181(9):1383-1403. PubMed ID: 37994108
[TBL] [Abstract] [Full Text] [Related]
14. Loss of KDM6B epigenetically confers resistance to lipotoxicity in nonalcoholic fatty liver disease-related HCC.
Hatano M; Akiyama Y; Shimada S; Yagi K; Akahoshi K; Itoh M; Tanabe M; Ogawa Y; Tanaka S
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37782459
[TBL] [Abstract] [Full Text] [Related]
15. Biological Functions of the KDM2 Family of Histone Demethylases.
Andricovich J; Tzatsos A
Adv Exp Med Biol; 2023; 1433():51-68. PubMed ID: 37751135
[TBL] [Abstract] [Full Text] [Related]
16. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.
Wang T; Zhang K; You F; Ma R; Yang N; Tian S; An G; Yang L
Life Sci; 2023 Oct; 331():122024. PubMed ID: 37574043
[TBL] [Abstract] [Full Text] [Related]
17. Fibronectin fragments generated by pancreatic trypsin act as endogenous inhibitors of pancreatic tumor growth.
Resovi A; Persichitti P; Brunelli L; Minoli L; Borsotti P; Garattini G; Tironi M; Dugnani E; Redegalli M; De Simone G; Pastorelli R; Bani MR; Piemonti L; Mosher DF; Giavazzi R; Taraboletti G; Belotti D
J Exp Clin Cancer Res; 2023 Aug; 42(1):201. PubMed ID: 37559126
[TBL] [Abstract] [Full Text] [Related]
18. Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine.
Song N; Guan X; Zhang S; Wang Y; Wang X; Lu Z; Chong D; Wang JY; Yu R; Yu W; Jiang T; Gu Y
Cell Death Dis; 2023 Aug; 14(8):499. PubMed ID: 37542062
[TBL] [Abstract] [Full Text] [Related]
19. Novel Benchmark Values for Open Major Anatomic Liver Resection in Non-cirrhotic Patients: A Multicentric Study of 44 International Expert Centers.
Sousa Da Silva RX; Breuer E; Shankar S; Kawakatsu S; Hołówko W; Santos Coelho J; Jeddou H; Sugiura T; Ghallab M; Da Silva D; Watanabe G; Botea F; Sakai N; Addeo P; Tzedakis S; Bartsch F; Balcer K; Lim C; Werey F; Lopez-Lopez V; Peralta Montero L; Sanchez Claria R; Leiting J; Vachharajani N; Hopping E; Torres OJM; Hirano S; Andel D; Hagendoorn J; Psica A; Ravaioli M; Ahn KS; Reese T; Montes LA; Gunasekaran G; Alcázar C; Lim JH; Haroon M; Lu Q; Castaldi A; Orimo T; Moeckli B; Abadía T; Ruffolo L; Dib Hasan J; Ratti F; Kauffmann EF; de Wilde RF; Polak WG; Boggi U; Aldrighetti L; McCormack L; Hernandez-Alejandro R; Serrablo A; Toso C; Taketomi A; Gugenheim J; Dong J; Hanif F; Park JS; Ramia JM; Schwartz M; Ramisch D; De Oliveira ML; Oldhafer KJ; Kang KJ; Cescon M; Lodge P; Rinkes IHMB; Noji T; Thomson JE; Goh SK; Chapman WC; Cleary SP; Pekolj J; Regimbeau JM; Scatton O; Truant S; Lang H; Fuks D; Bachellier P; Ohtsuka M; Popescu I; Hasegawa K; Lesurtel M; Adam R; Cherqui D; Uesaka K; Boudjema K; Pinto-Marques H; Grąt M; Petrowsky H; Ebata T; Prachalias A; Robles-Campos R; Clavien PA
Ann Surg; 2023 Nov; 278(5):748-755. PubMed ID: 37465950
[TBL] [Abstract] [Full Text] [Related]
20. IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer.
Lutz MS; Zekri L; Weßling L; Berchtold S; Heitmann JS; Lauer UM; Jung G; Salih HR
Front Immunol; 2023; 14():1163136. PubMed ID: 37122707
[TBL] [Abstract] [Full Text] [Related]
[Next]
